This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           November 12, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Bevacizumab plus fosbretabulin improves survival in ovarian cancer
The Oncology Report (Free login required)
The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A randomized, open-label, phase II study in 107 patients found a significant improvement in progression-free survival among patients treated with the combination of bevacizumab and fosbretabulin versus bevacizumab alone, with a median improvement of 2.5 months.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Annual Meeting early bird registration now open
Early bird registration for SGO’s 2015 Annual Meeting on Women’s Cancer is open until Monday, Jan. 26, 2015. Member/non-member fees and online registration are available on the SGO website. SGO Chicago-based members and staff have extended a special video invitation to all SGO members to “See You in Chicago” March 28-31.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


New research focuses on personalized treatments in ovarian cancer
Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches, said Michael J. Birrer, MD, PhD, of Harvard Medical School and Massachusetts General Hospital in a recent talk at the Chemotherapy Foundation Symposium in New York. He added that although “pathologists have been telling us for years that ovarian cancer doesn’t look the same under the microscope … We ignored them and they were right.”
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Use of hospital-based services, as well as hospice, increased among patients with ovarian cancer
Oncology Nurse Advisor
Patients with ovarian cancer were found to be more likely to enter a hospice and less likely to die in a hospital even though their use of hospital-based services actually increased, according to a study published in the Nov. 10 issue of the Journal of Clinical Oncology. Efforts have been widespread to improve the quality of life of terminally ill patients. As more patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. This study by Dana-Farber Cancer Institute researchers in Boston, Massachusetts, shows that this is not happening for one group of terminally ill cancer patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells
Molecular Cancer
The objective of the study published in the Nov. 1 issue of Molecular Cancer was to identify human epididymis protein 4 (HE4) interacting proteins and explore the mechanisms underlying their effect on ovarian cancer cell invasion and metastasis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Federal goal is to vaccinate 80 percent of boys and girls against HPV by 2020
The Wall Street Journal (Subscription required)
Public-health officials are pushing for higher HPV vaccination rates amid growing evidence that cancers linked to the virus are afflicting more men. The National Cancer Institute announced recently it is pouring nearly $2.7 million into 18 U.S. cancer centers to boost HPV vaccinations among boys and girls. The cancer centers will work with local health clinics to set recommendations for vaccinating against the sexually transmitted infection, which in some cases can cause cancers in men and women later in life.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


California hospital explores genetics-aided cancer treatment
The University of California San Francisco is exploring ways to gather and use genetic information gathered from cancer patients, hoping to break new ground in a fledgling field of genomic medicine. Working with Silicon Valley start-up Syapse, the project aims to to build a store of genetic data about various metastatic cancer cases with patients' consent, theoretically sharpening treatment or even coming up with new therapies.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Breast cancer margins, radiotherapy, axillary dissection evolve
The Oncology Report
Recent research and guidelines have changed how surgeons should be thinking about some aspects of treating breast cancer, a panel of experts said in a press briefing at the annual clinical congress of the American College of Surgeons. New guidelines on surgical margins, data supporting radiation rather than complete lymphadenectomy for patients with positive sentinel nodes, and other studies supporting targeted radiation therapy instead of whole-breast irradiation after lumpectomy should be on a surgeons’s radar, the speakers said.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Nov. 5, 2014
Oct. 29, 2014
Oct. 22, 2014
Oct. 8, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063